Abstract
Background: Parkinson’s disease (PD) is a neurodegenerative disease characterized by the loss of dopaminergic neurons within the substantia nigra pars compacta (SNpc). Despite many researches, there is still no cure for this disease. Levodopa is the first line treatment of PD, but the long term use of it leads to motor impairments and dyskinesias. The dopamine agonists are the preferred choice for the treatment of PD. They are neuroprotective in nature but have side effects.
Objective: Our aim was to review the work that has been carried out on dopamine agonists and the future possibilities to reduce their side effects.
Conclusion: In this review, we highlighted the metabolism of dopamine, different types of dopamine agonists with their properties and possible side effects.
Keywords: Neurodegenerative disease, dopamine, agonists, metabolism, neurotransmitters, central nervous system.
Current Drug Targets
Title:Dopamine: Agonists and Neurodegenerative Disorders
Volume: 19 Issue: 14
Author(s): Saba Khanam and Yasir Hasan Siddique*
Affiliation:
- Drosophila Transgenic Laboratory, Section of Genetics, Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University, Aligarh, Uttar Pradesh 202002,India
Keywords: Neurodegenerative disease, dopamine, agonists, metabolism, neurotransmitters, central nervous system.
Abstract: Background: Parkinson’s disease (PD) is a neurodegenerative disease characterized by the loss of dopaminergic neurons within the substantia nigra pars compacta (SNpc). Despite many researches, there is still no cure for this disease. Levodopa is the first line treatment of PD, but the long term use of it leads to motor impairments and dyskinesias. The dopamine agonists are the preferred choice for the treatment of PD. They are neuroprotective in nature but have side effects.
Objective: Our aim was to review the work that has been carried out on dopamine agonists and the future possibilities to reduce their side effects.
Conclusion: In this review, we highlighted the metabolism of dopamine, different types of dopamine agonists with their properties and possible side effects.
Export Options
About this article
Cite this article as:
Khanam Saba and Siddique Hasan Yasir*, Dopamine: Agonists and Neurodegenerative Disorders, Current Drug Targets 2018; 19 (14) . https://dx.doi.org/10.2174/1389450118666171117124340
DOI https://dx.doi.org/10.2174/1389450118666171117124340 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Parkinsonian Effects of Nurr1 Activator in Ubiquitin-Proteasome System Impairment Induced Animal Model of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Parkinsons Disease: Genetics and Beyond
Current Neuropharmacology Adenosine, Ketogenic Diet and Epilepsy: The Emerging Therapeutic Relationship Between Metabolism and Brain Activity
Current Neuropharmacology Pharmacological Therapy of Parkinson’s Disease: Current Options and New Avenues
Recent Patents on CNS Drug Discovery (Discontinued) COMMENTARY: Magnetic Resonance Techniques Applied to Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets The Role of Therapeutic Drugs on Acquired Mitochondrial Toxicity
Current Drug Metabolism Pharmacological Therapy of Cushings Syndrome: Drugs and Indications
Mini-Reviews in Medicinal Chemistry Noradrenergic System in Down Syndrome and Alzheimer’s Disease A Target for Therapy
Current Alzheimer Research Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders
Current Drug Therapy Clinical Values of Nitric Oxide Parameters from the Respiratory System
Current Medicinal Chemistry Mood and Anxiety Disorders in Breast Cancer: An Update
Current Psychiatry Reviews Homology Modeling of Adenosine A2A Receptor and Molecular Docking for Exploration of Appropriate Potent Antagonists for Treatment of Parkinsons Disease
Current Aging Science Deprescribing for Psychiatry: The Right Prescription?
Current Psychiatry Reviews Conditioned Avoidance Response in the Development of New Antipsychotics
Current Pharmaceutical Design Potential for the Rational Design of Allosteric Modulators of Class C GPCRs
Current Topics in Medicinal Chemistry Bis(thiosemicarbazone) Metal Complexes as Therapeutics for Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Adult Neural Stem Cell Therapy: Expansion In Vitro, Tracking In Vivo and Clinical Transplantation
Current Drug Targets Modulation Effects of Piracetam and Ginkgo biloba on the Cognitive and Working Memory Functions: Psychometric Study
Current Psychopharmacology Serotonin 5-HT<sub>1A</sub> Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs
Current Pharmaceutical Design Development and Applications of Non-HIV-Based Lentiviral Vectors in Neurological Disorders
Current Gene Therapy